February 08, 2016 - 5:02 p.m.
Gilead Sciences to Participate in Two Upcoming Investor Conferences
Printer Friendly Version 
February 02, 2016 - 4:02 p.m.
Gilead Sciences Announces Declaration of Q1 Cash Dividend and Increases to Shareholder Return Programs
Printer Friendly Version 
February 02, 2016 - 4:01 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results
Printer Friendly Version 
February 01, 2016 - 5:00 p.m.
Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources
Printer Friendly Version 
February 01, 2016 - 9:04 a.m.
European Medicines Agency Validates Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Printer Friendly Version 
January 29, 2016 - 8:00 a.m.
Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director
Printer Friendly Version 
January 26, 2016 - 5:01 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2015 Financial Results on Tuesday, February 2, 2016
Printer Friendly Version 
January 19, 2016 - 4:31 p.m.
Galapagos and Gilead Complete Closing of Their Global Collaboration for Filgotinib
Printer Friendly Version 
January 13, 2016 - 1:31 a.m.
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
Printer Friendly Version 
January 12, 2016 - 8:31 a.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
January 08, 2016 - 4:01 p.m.
Gilead Sciences to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11
Printer Friendly Version 
January 05, 2016 - 6:01 p.m.
Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis
Printer Friendly Version 
January 05, 2016 - 8:31 a.m.
Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
Printer Friendly Version 
January 04, 2016 - 4:31 p.m.
Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection
Printer Friendly Version 
NASDAQ (US Dollar)
$87.36
 Stock is Down 0.44 (0.50%)
Data as of 02/11/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote